Cutaquig Solution
Product Images NDC 0069-1965

Product Visual Gallery

This gallery contains 25 technical images submitted to the FDA as part of the official labeling for Cutaquig (NDC 0069-1965). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pfizer Laboratories Div Pfizer Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Image File (Img0001)

A text panel showing a dosing calculation for an initial weekly dose of immunoglobulin G, which is determined by multiplying the previous IGIV dose in grams by 1.30 and dividing by the number of weeks between IGIV doses.*

FDA Label Image

Image File (Img0002)

A data table displaying weight-adjusted dose increments (in mL) for Cutaquig (immunoglobulin G) based on difference from target serum IgG trough levels (50 to 300 mg/dl), dosing frequency (weekly or every other week), and body weights ranging from 30 kg to 110 kg.*

FDA Label Image

Image File (Img0003)

An illustration showing a person washing their hands under a running faucet, with water flowing over their fingers into a sink basin. The image emphasizes hand hygiene practices, depicting a close-up of hands beneath the water stream.*

FDA Label Image

Image File (Img0004)

An instructional illustration showing hands opening a vial by removing a protective cap. The image is related to the preparation of Cutaquig, an immunoglobulin G solution for subcutaneous injection provided by Pfizer Laboratories.*

FDA Label Image

Image File (Img0005)

An instructional illustration showing hands preparing a syringe by attaching a needle or removing a cap, indicated by a downward arrow. This image likely demonstrates a step in the preparation or administration of Cutaquig subcutaneous immunoglobulin G solution.*

FDA Label Image

Image File (Img0006)

An illustration showing two hands holding parts of a medical device used for subcutaneous delivery, featuring a syringe-like mechanism attached to tubing. This likely demonstrates preparation or administration of a subcutaneous solution such as Cutaquig (immunoglobulin G).*

FDA Label Image

Image File (Img0007)

An anatomical diagram depicting front and back views of a male torso and legs. Colored areas highlight recommended subcutaneous injection sites for immunoglobulin G solution, including the abdomen, upper arms, thighs, and lower back regions.*

FDA Label Image

Image File (Img0008)

An illustration showing a close-up of a person pinching the skin on their abdomen, likely demonstrating the subcutaneous injection site technique, relevant to subcutaneous administration of medications such as Cutaquig, an immunoglobulin G solution.*

FDA Label Image

Image File (Img0009)

An instructional illustration showing a hand inserting a needle subcutaneously into the abdomen to administer a subcutaneous infusion. A catheter or tube is attached to the needle, secured with adhesive, and connected to an infusion device or pump at the waist, demonstrating a typical setup for subcutaneous delivery of medication such as immunoglobulin G solution.*

FDA Label Image

Image File (Img0010)

An illustration showing the subcutaneous administration of Cutaquig solution, with a tubing and small bandaged catheter inserted into the skin on the abdomen near the waistline, illustrating the typical site for injection.*

FDA Label Image

Image File (Img0011)

A data table presenting the in vitro reduction factors (log10) for enveloped viruses (HIV-1, PRV, SBV) and non-enveloped viruses (MEV, PPV) across production steps of ethanol fractionation, S/D treatment, and pH4 treatment, including the global reduction factor summary for each virus type.*

FDA Label Image

Image File (Img0012)

An illustration showing a pair of hands being rinsed under running water from a faucet, demonstrating proper handwashing or cleansing technique, likely relevant to preparation or hygiene before administering a subcutaneous solution like Cutaquig immunoglobulin G.*

FDA Label Image

Image File (Img0013)

An instructional illustration showing a person removing the protective seal from the top of a medication vial with their fingers. The image demonstrates preparation steps likely related to using a vial for subcutaneous injection.*

FDA Label Image

Image File (Img0014)

An instructional illustration showing how to hold and manipulate a vial and syringe for preparation or administration. One hand holds the vial upside down while the other hand holds the syringe with an arrow indicating the syringing direction.*

FDA Label Image

Image File (Img0015)

An instructional illustration showing hands holding a syringe connected to tubing, indicating preparation or administration of a subcutaneous solution. The image appears to demonstrate handling or setup of a subcutaneous injection device.*

FDA Label Image

Image File (Img0016)

Illustration showing recommended subcutaneous injection sites for Cutaquig (immunoglobulin G 165 mg/mL solution). Front view highlights blue areas on the abdomen and upper arms, and green areas on the inner thighs and lower abdomen. Rear view indicates blue injection sites on the upper back, lower back, and backs of the thighs.*

FDA Label Image

Image File (Img0017)

An illustration showing a person pinching the skin of the lower abdomen, just above the belt line, likely demonstrating a subcutaneous injection site.*

FDA Label Image

Image File (Img0018)

An instructional illustration showing a hand inserting a needle with tubing into the subcutaneous tissue of an abdomen, demonstrating the administration technique commonly used for subcutaneous immunoglobulin G solution such as Cutaquig.*

FDA Label Image

Image File (Img0019)

Illustration showing subcutaneous administration with a needle inserted under the skin on the abdomen, secured by a small adhesive bandage. The tubing is connected to the injection site, positioned near the waistband of pants.*

FDA Label Image

Image File (Img0020)

Packaging label for Cutaquig 1 g/6 mL subcutaneous solution, containing immunoglobulin G 165 mg/mL, distributed by Pfizer Labs. The label includes storage instructions, manufacturer details (Octapharma Pharmazeutika Produktionsges.m.b.H., Austria), composition, and barcode. The label emphasizes subcutaneous use only and states the product is sterile with no preservatives.*

FDA Label Image

Image File (Img0021)

The packaging label is for Cutaquig 165 mg/mL solution, a subcutaneous immune globulin G product. The 10 mL vial is produced by Pfizer Laboratories Division of Pfizer Inc and manufactured by Octapharma Pharmazeutika in Austria. The label includes storage instructions, ingredients, and a barcode.*

FDA Label Image

Image File (Img0022)

Packaging label for Cutaquig 2 g/12 mL solution, a subcutaneous immunoglobulin G 16.5% plasma derivative. The label includes product name, strength, dosage form, route, storage instructions, manufacturer Octapharma, and distributor Pfizer Labs. It contains ingredient and preservative information, barcode, and regulatory codes, with a white and light teal color scheme.*

FDA Label Image

Image File (Img0023)

Packaging label for Cutaquig 3.3 g/20 mL solution, a subcutaneous immune globulin (human) product with 16.5% strength. The label indicates storage instructions, contents per mL (immunoglobulin G 165 mg, maltose, polysorbate 80, water for injection), manufacturer details (Octapharma Pharmazeutika, Austria), and distributor Pfizer Labs.*

FDA Label Image

Image File (Img0024)

Cutaquig 4 g/24 mL immune globulin subcutaneous solution (human) 16.5%, labeled as for subcutaneous use only. The label shows 4 g strength in 24 mL, includes storage instructions, manufacturer details (Octapharma Pharmazeutika Produktionsges.m.b.H., Vienna, Austria), and the distributor Pfizer Laboratories Division Pfizer Inc. It lists ingredients including protein 165 mg, maltose, polysorbate 80, and water for injection.*

FDA Label Image

Image File (Img0025)

Packaging label for Cutaquig 16.5% (165 mg/mL) immunoglobulin G subcutaneous solution in an 8 g / 48 mL bottle. The label indicates the product is solvent/detergent and pH4 treated, for subcutaneous use only, and sterile with no preservatives. It is manufactured by Octapharma Pharmazeutika Produktionsges.m.b.H. in Austria and distributed by Pfizer Labs, Division of Pfizer Inc. Additional storage and ingredient information is included.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.